Compare WD & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WD | NUVB |
|---|---|---|
| Founded | 1937 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2010 | 2020 |
| Metric | WD | NUVB |
|---|---|---|
| Price | $40.35 | $6.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $76.00 | $11.38 |
| AVG Volume (30 Days) | 393.1K | ★ 5.9M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | ★ 5.34% | N/A |
| EPS Growth | N/A | ★ 71.56 |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $1,234,306,000.00 | $62,902,000.00 |
| Revenue This Year | $20.60 | $203.82 |
| Revenue Next Year | $7.79 | $58.18 |
| P/E Ratio | $73.05 | ★ N/A |
| Revenue Growth | 8.99 | ★ 698.96 |
| 52 Week Low | $39.45 | $2.84 |
| 52 Week High | $90.00 | $9.75 |
| Indicator | WD | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 32.36 | 58.62 |
| Support Level | N/A | $5.28 |
| Resistance Level | $52.37 | $8.95 |
| Average True Range (ATR) | 2.10 | 0.38 |
| MACD | -0.46 | 0.03 |
| Stochastic Oscillator | 5.53 | 60.88 |
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of its total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.